Chordate enrolls first patients in a randomized, placebo-controlled, double-blind, multicenter study to evaluate the efficacy of intranasal kinetic oscillation stimulation in the treatment of chronic non-allergic rhinitis 2018-05-08

Chordate enrolls first patients in a randomized, placebo-controlled, double-blind, multicenter study to evaluate the efficacy of intranasal kinetic oscillation stimulation in the treatment of chronic non-allergic rhinitis Data Anticipated Q4 2019 Kista, Sweden, May 08, 2018 — Chordate Medical Holding AB’s (publ) (“Chordate”), a specialty medtech company that focuses on developing and commercializing neuromodulating treatment systems for treating non-allergic rhinitis and migraine, today announced that […]

Chordate enrolls first patient in a study to evaluate the efficacy of intranasal kinetic oscillation stimulation in the preventive treatment of chronic migraine 2018-03-23

Chordate enrolls first patient in a randomized, placebo-controlled, double-blind, multicenter study to evaluate the efficacy of intranasal kinetic oscillation stimulation in the preventive treatment of chronic migraine. Kista, Sweden, March 23, 2018 — Chordate Medical Holding AB’s (publ) (“Chordate”), a specialty medtech company that focuses on developing and commercializing neuromodulating treatment systems for treating non-allergic rhinitis and migraine, today announced that the first patient was […]

CHORDATE WILL PARTICIPATE IN EUROPEAN RHINOLOGIC SOCIETY MEETING 2018-03-21

Chordate Medical will participate in European Rhinologic Society Meeting (ERS) in London 22-26 April. http://www.erslondon2018.com/

CHORDATE AND STERIPOLAR EXHIBIT DURING ENT-CONGRESS 2018-02-08

Together with Steripolar, Chordate exhibits during the ENT-congress in Helsinki, Finland February 8-9.

CHORDATE SIGNS DISTRIBUTION AGREEMENT FOR FINLAND 2018-02-05

Chordate signs distribution agreement with Steripolar for Finland.